Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]

Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]

<p>Abstract</p> <p>Background</p> <p>The aim of this study was to evaluate the long-term efficacy and tolerability of etoricoxib, a COX-2 selective inhibitor, in osteoarthritis (OA) patients.</p> <p>Methods</p> <p>A double-blind, randomized, mult...

Full description

Bibliographic Details
Main Authors: Olaleye Joseph, Fisher Chester, Bockow Barry, Curtis Sean P, Compton Amy, Ko Amy T, Reicin Alise S
Format: Article
Language:English
Published: BMC 2005-12-01
Series:BMC Musculoskeletal Disorders
Online Access:http://www.biomedcentral.com/1471-2474/6/58

Similar Items

Similar Items